Schedule III rescheduling: what it actually means for federal inmates and federal workers

On April 22, 2026, Acting Attorney General Todd Blanche signed a final order — effective April 23, 2026 — moving a narrow category of marijuana products from Schedule I to Schedule III of the federal Controlled Substances Act. This is a historic shift, but its scope is bounded: it does not legalize marijuana, does not change federal workplace drug testing, and does not give federal inmates a right to use cannabis in custody. Here is what actually changed, and what did not.

Overview — what changed on April 23, 2026

The April 22 final order moved two specific categories to Schedule III: FDA-approved drug products containing marijuana (currently Epidiolex, Marinol, Syndros, and Cesamet), and marijuana regulated under a qualifying state-issued medical marijuana license. A separate Department of Justice action set an expedited DEA administrative hearing beginning June 29, 2026, concluding no later than July 15, 2026, to consider whether all marijuana — including recreational and unlicensed — should also move to Schedule III.

What the April 23 order did not do, and what often gets lost in headlines: it did not legalize marijuana federally, did not move recreational or unlicensed marijuana out of Schedule I, did not create a federal prescription pathway for state-program medical cannabis, and did not change federal workplace drug testing rules. Schedule III is a narrow legal pathway for regulated medical research and FDA-supervised prescribing — not a blanket permission for federal employees or federal inmates to use marijuana.

For federal inmates and their families

The short version: no, not as a practical right. The April 23 order does not allow federal inmates to possess or use marijuana inside BOP custody — even with a state medical card, even in a state where their family lives that has legalized medical or recreational use.

Two layers of BOP policy control this. First, discipline: under 28 CFR § 541.3 (Prohibited Acts and Available Sanctions), use or possession of narcotics, marijuana, or related paraphernalia without prior authorization by the medical staff is a high-severity prohibited act (Code 113 — use of any narcotics, marijuana, drugs, alcohol, intoxicants, or related paraphernalia; Code 112 — use of any narcotics/marijuana/drugs/intoxicants not prescribed for the individual by the medical staff). Sanctions include loss of good conduct time, disciplinary segregation, and loss of visitation, commissary, and phone privileges.

Second, medication access: BOP Program Statement 6360.02 (Pharmacy Services) requires all medications dispensed inside a BOP facility to come through the institution pharmacy under the National Drug Formulary or an approved non-formulary request. An outside physician's prescription — whether for a Schedule III drug or any other — does not authorize in-custody possession unless BOP medical staff orders and dispenses it through the pharmacy.

In practical terms, Schedule III status could eventually create a narrow pathway for BOP medical staff to prescribe and dispense an FDA-approved marijuana product (for example, Epidiolex for a specific seizure disorder, or Marinol for appetite loss in chemotherapy or HIV wasting) if the clinical indication fit BOP's formulary process and the non-formulary drug authorization procedure. State medical marijuana cards, outside "prescriptions" that are actually recommendations, recreational use, and any smoked, vaped, or edible cannabis product obtained outside BOP pharmacy remain prohibited regardless of Schedule III status.

Furlough conditions (BP-A0291) also still apply. The standard furlough agreement expressly prohibits the purchase, possession, use, consumption, or administration of narcotics, marijuana, or intoxicants in any form while on furlough — including in states where marijuana is legal. Violation is grounds for disciplinary action on return and, in some cases, prosecution for escape or violation of conditions.

What to do this week if your loved one is in BOP custody

1. Do not send, mail, attempt to deliver, or attempt to coordinate delivery of any marijuana product to a federal inmate. Nothing in the April 23 order changes the criminal exposure for doing so.
2. Do not encourage an inmate on furlough to use marijuana, even legally under state law. The BP-A0291 prohibition is independent of state law.
3. If your loved one has a legitimate clinical need that might be met by an FDA-approved cannabinoid medication (Epidiolex, Marinol, Syndros, Cesamet), the pathway is a formal request through institution medical staff, not an outside prescription. Ask your loved one to raise it with their Clinical Director or PA at sick call, and be prepared for a non-formulary drug authorization process.
4. If your loved one is disciplined under Code 112 or 113 based on conduct that occurred before April 23, 2026, Schedule III rescheduling does not retroactively void the incident report. Administrative remedy (BP-8 → BP-9 → BP-10 → BP-11) remains the correct pathway for challenges.

For federal workers

The short version: assume the answer is no unless your agency's drug program coordinator, Medical Review Officer, and — if applicable — security office tell you yes in writing.

Federal employees remain subject to the Drug-Free Workplace Act of 1988 (41 U.S.C. § 8103), which requires federal workplaces to maintain drug-free conditions and federal employees to avoid illegal drug use. Schedule III status does not repeal that Act. Federal testing programs operate under HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs (commonly called the "SAMHSA panel"), which continue to list marijuana as a tested substance pending a separate HHS rule update. No such update has been published as of this writing.

A medical marijuana card or physician recommendation issued under a state program is not the same as a DEA-valid prescription. The April 23 order kept that distinction intentionally: state-licensed medical operators can now register with DEA and handle marijuana under federal registration, but physicians do not yet issue federal prescriptions for state-program marijuana. The FDA-approved products (Epidiolex, Marinol, Syndros, Cesamet) have always been federally prescribable — that part is unchanged.

Security clearance holders face an additional layer. Security Executive Agent Directive 4 (SEAD-4) and its adjudicative guidelines — specifically Guideline E (personal conduct), Guideline H (drug involvement), and Guideline J (criminal conduct) — still treat marijuana use as a potential concern. Rescheduling does not automatically update SEAD-4, and adjudicators evaluate whether use was consistent with federal law at the time it occurred. Past use does not retroactively become non-disqualifying.

Safety-sensitive roles have their own regime. DOT-regulated employees (CDL drivers, pilots, transit, rail, pipeline, maritime) are governed by 49 CFR Part 40, which on December 19, 2025, was the subject of a DOT compliance notice stating marijuana testing continues unchanged pending further guidance. BOP employees, federal law enforcement, military personnel, and TSA-regulated workers operate under policies that have not been updated to reflect the April 23 order.

What to do this week if you are a federal worker or contractor

1. Do not assume your own agency's policy has changed. Ask your drug program coordinator or HR in writing. Save the response.
2. If you hold a clearance, consult your security officer before any use, even in a state where it is legal. Verbal reassurance from a supervisor is not protection.
3. If you are DOT-regulated, continue to treat marijuana as prohibited. The DOT December 19, 2025 compliance notice is the operative guidance until further DOT rulemaking.
4. If you have an existing prescription for an FDA-approved marijuana product (Epidiolex, Marinol, Syndros, Cesamet), disclose it to your MRO the same way you would any other prescription. These were already lawful with a valid prescription.

Bottom line

Schedule III rescheduling of a narrow category of marijuana is historic and opens legitimate pathways for FDA-supervised research and regulated medical use. It does not create a right for federal workers to use cannabis, and it does not create a right for federal inmates to possess or use cannabis in custody. Until SAMHSA updates its testing guidelines, until DOT and the clearance agencies update their policies, and until BOP's pharmacy and discipline programs address Schedule III specifically, the operative rule for federal employees and federal inmates is unchanged: assume no, verify before acting, and document every decision in writing.